Leads Biolabs Publishes 2026 AGM Agenda: 2025 Results, EY Re-appointment, Share Mandates and Board Changes

Bulletin Express04-24

Leads Biolabs (南京維立志博生物科技股份有限公司) has issued the proxy form and agenda for its Annual General Meeting (AGM) scheduled for 10:00 a.m. on Friday, 15 May 2026, at the Company’s headquarters on Floor 6, Building 03, 18E Jialingjiang Street, Nanjing.

Key proposals to be tabled:

1. 2025 Operating and Financial Review • Shareholders will vote on the Board’s work report, the final financial report, and the full annual report for the 2025 fiscal year. • A 2025 profit-distribution plan is proposed; specific payout figures are not disclosed in the current notice.

2. Board Composition • Appointment of Dr. Wu Fenglan as a non-executive director is up for approval.

3. Auditor Engagement • Ernst & Young is nominated for re-appointment as external auditor for 2026, with the Board authorised to set remuneration.

4. Directors’ Remuneration • A remuneration plan covering directors for 2026 will be presented for shareholder endorsement.

5. Capital Management Mandates • A general mandate authorising the Board to allot, issue, and deal with additional shares—including the sale or transfer of treasury shares—will be sought. • A separate mandate to repurchase H shares on the open market is proposed.

6. Governance Update • Amendments to the Articles of Association will be submitted for shareholder approval.

Shareholders unable to attend may appoint proxies by submitting completed forms no later than 10:00 a.m. on Thursday, 14 May 2026, to either Computershare Hong Kong Investor Services Limited (for H shareholders) or the Company’s Nanjing office (for unlisted shareholders).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167235046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167235046","market":"us","top_or_hot":-1,"title":"Leads Biolabs Publishes 2026 AGM Agenda: 2025 Results, EY Re-appointment, Share Mandates and Board Changes","media":"Bulletin Express","content":"<p>Leads Biolabs (南京維立志博生物科技股份有限公司) has issued the proxy form and agenda for its Annual General Meeting (AGM) scheduled for 10:00 a.m. on Friday, 15 May 2026, at the Company’s headquarters on Floor 6, Building 03, 18E Jialingjiang Street, Nanjing.</p>\n<p>Key proposals to be tabled:</p>\n<p>1. 2025 Operating and Financial Review  \n   • Shareholders will vote on the Board’s work report, the final financial report, and the full annual report for the 2025 fiscal year.  \n   • A 2025 profit-distribution plan is proposed; specific payout figures are not disclosed in the current notice.</p>\n<p>2. Board Composition  \n   • Appointment of Dr. Wu Fenglan as a non-executive director is up for approval.</p>\n<p>3. Auditor Engagement  \n   • Ernst & Young is nominated for re-appointment as external auditor for 2026, with the Board authorised to set remuneration.</p>\n<p>4. Directors’ Remuneration  \n   • A remuneration plan covering directors for 2026 will be presented for shareholder endorsement.</p>\n<p>5. Capital Management Mandates  \n   • A general mandate authorising the Board to allot, issue, and deal with additional shares—including the sale or transfer of treasury shares—will be sought.  \n   • A separate mandate to repurchase H shares on the open market is proposed.</p>\n<p>6. Governance Update  \n   • Amendments to the Articles of Association will be submitted for shareholder approval.</p>\n<p>Shareholders unable to attend may appoint proxies by submitting completed forms no later than 10:00 a.m. on Thursday, 14 May 2026, to either Computershare Hong Kong Investor Services Limited (for H shareholders) or the Company’s Nanjing office (for unlisted shareholders).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leads Biolabs Publishes 2026 AGM Agenda: 2025 Results, EY Re-appointment, Share Mandates and Board Changes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeads Biolabs Publishes 2026 AGM Agenda: 2025 Results, EY Re-appointment, Share Mandates and Board Changes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-24 22:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Leads Biolabs (南京維立志博生物科技股份有限公司) has issued the proxy form and agenda for its Annual General Meeting (AGM) scheduled for 10:00 a.m. on Friday, 15 May 2026, at the Company’s headquarters on Floor 6, Building 03, 18E Jialingjiang Street, Nanjing.</p>\n<p>Key proposals to be tabled:</p>\n<p>1. 2025 Operating and Financial Review  \n   • Shareholders will vote on the Board’s work report, the final financial report, and the full annual report for the 2025 fiscal year.  \n   • A 2025 profit-distribution plan is proposed; specific payout figures are not disclosed in the current notice.</p>\n<p>2. Board Composition  \n   • Appointment of Dr. Wu Fenglan as a non-executive director is up for approval.</p>\n<p>3. Auditor Engagement  \n   • Ernst & Young is nominated for re-appointment as external auditor for 2026, with the Board authorised to set remuneration.</p>\n<p>4. Directors’ Remuneration  \n   • A remuneration plan covering directors for 2026 will be presented for shareholder endorsement.</p>\n<p>5. Capital Management Mandates  \n   • A general mandate authorising the Board to allot, issue, and deal with additional shares—including the sale or transfer of treasury shares—will be sought.  \n   • A separate mandate to repurchase H shares on the open market is proposed.</p>\n<p>6. Governance Update  \n   • Amendments to the Articles of Association will be submitted for shareholder approval.</p>\n<p>Shareholders unable to attend may appoint proxies by submitting completed forms no later than 10:00 a.m. on Thursday, 14 May 2026, to either Computershare Hong Kong Investor Services Limited (for H shareholders) or the Company’s Nanjing office (for unlisted shareholders).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1167235046","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167235046","pubTimestamp":1777040585,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Leads Biolabs (南京維立志博生物科技股份有限公司) has issued the proxy form and agenda for its Annual General Meeting (AGM) scheduled for 10:00 a.m. on Friday, 15 May 2026, at the Company’s headquarters on Floor 6,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"Leads Biolabs发布2026年年度股东大会议程：2025年业绩、安永连任、股份授权和董事会变动","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"Leads Biolabs (南京維立志博生物科技股份有限公司) has issued the proxy form and agenda for its Annual General Meeting (AGM) scheduled for 10:00 a.m. on Friday, 15 May 2026, at the Company’s headquarters on Floor 6, Building 03, 18E Jialingjiang Street, Nanjing.\nKey proposals to be tabled:\n1. 2025 Operating and Financial Review  \n   • Shareholders will vote on the Board’s work report, the final financial report, and the full annual report for the 2025 fiscal year.  \n   • A 2025 profit-distribution plan is proposed; specific payout figures are not disclosed in the current notice.\n2. Board Composition  \n   • Appointment of Dr. Wu Fenglan as a non-executive director is up for approval.\n3. Auditor Engagement  \n   • Ernst & Young is nominated for re-appointment as external auditor for 2026, with the Board authorised to set remuneration.\n4. Directors’ Remuneration  \n   • A remuneration plan covering directors for 2026 will be presented for shareholder endorsement.\n5. Capital Management Mandates  \n   • A general mandate authorising the Board to allot, issue, and deal with additional shares—including the sale or transfer of treasury shares—will be sought.  \n   • A separate mandate to repurchase H shares on the open market is proposed.\n6. Governance Update  \n   • Amendments to the Articles of Association will be submitted for shareholder approval.\nShareholders unable to attend may appoint proxies by submitting completed forms no later than 10:00 a.m. on Thursday, 14 May 2026, to either Computershare Hong Kong Investor Services Limited (for H shareholders) or the Company’s Nanjing office (for unlisted shareholders).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167235046","isCrawlerRequest":true}